Macconi Letizia, Galici Valeria, Di Maurizio Marco, Rossi Enrica, Taccetti Giovanni, Terlizzi Vito
Department of Radiology, Meyer Children's Hospital, 50139 Florence, Italy.
Department of Paediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital, 50139 Florence, Italy.
J Clin Med. 2022 Jul 22;11(15):4277. doi: 10.3390/jcm11154277.
This is a prospective, observational study involving three Cystic Fibrosis (CF) adult patients, evaluating the changes in chest magnetic resonance imaging (MRI) three months after the start of elexacaftor/tezacaftor and ivacaftor therapy. MRI showed a drastic reduction in mucus plugging and bronchial wall thickening, with an improvement in the diffusion-weighted MRI score. Similarly, a marked improvement in spirometric parameters, nutritional status, and sweat chloride was observed. Our preliminary data confirm that chest MRI could be a useful tool to assess disease progression in CF patients on modulatory drug therapy.
这是一项前瞻性观察性研究，涉及三名成年囊性纤维化（CF）患者，评估在开始使用依列卡福/替扎卡福和依伐卡托治疗三个月后胸部磁共振成像（MRI）的变化。MRI显示黏液阻塞和支气管壁增厚明显减轻，扩散加权MRI评分有所改善。同样，观察到肺功能参数、营养状况和汗液氯化物水平有显著改善。我们的初步数据证实，胸部MRI可能是评估接受调节药物治疗的CF患者疾病进展的有用工具。
